The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.
Celgene Corporation entered into a global license agreement with Nogra Pharma Limited, a private...
Valeant Pharmaceuticals International says three of its directors will not stand for re-election...
Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.
Beckman Coulter Life Sciences has entered into an agreement to acquire Xitogen Technologies Inc. together with Cytojene Corporation. Xitogen, a flow cytometer developer based in Suzhou and Dalian, China, will provide Beckman Coulter Life Sciences with both a strong operational base in the growing China market and a high quality research instrument to round out their world-class cytometry offering.
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.
Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.
Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.
Aastrom Biosciences announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million.
Actavis has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech.
BioAlliance Pharma SA and Topotarget A/S today announced their intention to merge to create an orphan oncology company with a highly complementary pipeline of late-stage products addressing significant unmet medical needs.
Epirus Biopharmaceuticals, Inc. and Zalicus Inc., announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.
Moberg Pharma AB has entered into a definitive agreement with Oracain II Aps (Denmark) to acquire all assets and global rights to a novel and patent pending oral formulation of the proven substance bupivacaine, for the treatment of pain in the oral cavity.
Will Sun’s latest acquisition change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?
Swiss drug maker Roche plans to buy IQuum, Inc., a U.S. company that specializes in molecular diagnostics and sample testing, in a deal worth up to $450 million.
India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion deal, the companies said Monday.
Mallinckrodt is buying California-based Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.2 billion that will help to diversify further the Irish company's business.
Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions."
Actavis today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.
RestorGenex Corporation announced today the closing of its acquisition of two biopharmaceuticals companies, Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc.
Nordion Inc., a provider of products and services to the global health science market, announced that it has entered into a definitive agreement to be acquired by Sterigenics, a provider of sterilization services and a portfolio company of GTCR LLC.
Otsuka Pharmaceutical Co., Ltd.has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen ® and to an enzyme inhibitor, E7727.
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5M.
Johnson & Johnson today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments.
AMRI has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million.
Horizon Pharma Inc. will acquire Vidara Therapeutics for a "tax-efficient corporate structure."
Horizon Pharma Inc. plans to buy the privately held Vidara Therapeutics International Ltd. in a cash-and-stock deal that will add the immune system disorder drug Actimmune to the specialty drugmaker's product portfolio.
Mallinckrodt plc (NYSE:MNK) today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion.
- Page 1